Nerve Blocks App
Anesthesia Assistant App
US Pain Management App
Pain Medicine Assistant App
POCUS App
IV Access App
MSK Knee App
VetRA App
Nerve Block Manual
Regional Anesthesia Updates
Anesthesiology Manual
Anesthesiology Review
Anesthesia Updates 2025
Anesthesia Updates 2026
Pediatric Anesthesia Updates
Airway Management Updates
US Interventional Pain Manual
Pain Medicine Updates
Mastering Difficult IV Access
PACU Nursing Manual
RA Veterinary Manual
Books
About
Learning objectives
- Describe tumor lysis syndrome (TLS)
- Management of TLS
Definition and mechanisms
- Tumor lysis syndrome (TLS) is a condition that occurs when a large number of cancer cells die within a short period, releasing their contents into the blood
- Occurs most commonly after the treatment of lymphomas and leukemias and in particular when treating non-Hodgkin lymphoma, acute myeloid leukemia, and acute lymphoblastic leukemia
- TLS can occur spontaneously (before cancer treatment) but is more common within a week of starting treatment
- Not limited to patients receiving traditional chemotherapy, can also occur in patients receiving steroids, hormonal therapy, targeted therapy, or radiation therapy
- Characterized by hyperkalemia, hyperphosphatemia, hypocalcemia, hyperuricemia, and higher-than-normal levels of blood urea nitrogen (BUN)
- TLS is analogous to rhabdomyolysis
Signs and symptoms
- Nausea with or without vomiting
- Lack of appetite and fatigue
- Dark urine, reduced urine output, or flank pain
- Numbness, seizures, or hallucinations
- Muscle cramps and spasms
- Heart palpitations
- Hyperkalemia and secondary arrhythmias
- Hyperphosphatemia and prologued QT interval
- Hypocalcemia and risk of seizures
- Hyperuricemia and acute renal failure
- Hyperuricosuria
Complications
- Acute uric acid nephropathy
- Acute kidney failure
- Seizures
- Cardiac arrhythmias
Risk factors
| Tumor characteristics | High cell turnover rate Rapid growth rate High tumor bulk |
| Type of cancer | Burkitt’s lymphoma Other Non-Hodgkin lymphomas Acute lymphoblastic leukemia Acute myeloid leukemia |
| Patient characteristics | Baseline serum creatine Kidney failure Dehydration |
| Chemotherapy characteristics | Chemo-sensitive tumors, such as lymphomas Use of steroids |
| Spontaneous tumor lysis syndrome | Triggered without any treatment |
Diagnosis
- Large tumor burden
- Hyperuricemia > 15 mg/dL
- Hyperphosphatemia > 8 mg/d
- Urine analysis: uric acid crystals or amorphous urates
- Detection of hypersecretion of uric acid with a high urine uric acid/creatinine ratio > 1.0
Management
Suggested reading
- Puri I, Sharma D, Gunturu KS, Ahmed AA. Diagnosis and management of tumor lysis syndrome. J Community Hosp Intern Med Perspect. 2020;10(3):269-272.
- Gupta, A., Moore, J.A., 2018. Tumor Lysis Syndrome. JAMA Oncology 4, 895.
- Oduro-Dominah L, Brennan LJ. Anaesthetic management of the child with haematological malignancy. Continuing Education in Anaesthesia Critical Care & Pain. 2013. 13;(5);158-164.
- Behl D, Hendrickson AW, Moynihan TJ. Oncologic emergencies. Crit Care Clin. 2010;26(1):181-205.
- Beed M, Levitt M, Bokhari SW. Intensive care management of patients with haematological malignancy. Continuing Education in Anaesthesia Critical Care & Pain. 2010.10;(6);167–171.
